Showing results (151-160 of 300) with videos related to

Sort By:
Pageof 30
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2020
Bevacizumab Plus mFOLFOX6 Versus mFOLFOX6 Alone as First-Line Treatment for <i>RAS</i> Mutant Unresectable Colorectal Liver-Limited Metastases: The BECOME Randomized Controlled TrialWentao Tang, Li Ren, Tianshu Liu, et al.
Japanese Journal of Clinical Oncology|May 3, 2018
Efficacy and safety comparison of nabpaclitaxel plus S-1 and gemcitabine plus S-1 as first-line chemotherapy for metastatic pancreatic cancerYaolin Xu, Xi Guo, Yue Fan, et al.
Journal of Clinical Laboratory Analysis|August 17, 2021
Cross-platform comparison of next-generation sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for detecting KRAS/NRAS/BRAF/PIK3CA mutations in cfDNA from metastatic colorectal cancer patientsXiaojing Xu, Fei Huang, Minlu Cao, et al.
Aging|November 19, 2019
Late stage gastric cancer patients with extra gained HER2 positivity by dual block assessment may not show compromised efficacy to trastuzumab treatmentChen Xu, Yalan Liu, Dongxian Jiang, et al.
Oncotarget|November 9, 2016
FoxO3a confers cetuximab resistance in RAS wild-type metastatic colorectal cancer through c-MycYiyi Yu, Mengzhou Guo, Ye Wei, et al.
Echocardiography (Mount Kisco, N.Y.)|October 17, 2023
Left atrial strain brings new insights for evaluating early diastolic dysfunction in patients with well-functioning bicuspid aortic valveYuting Tan, Wenhui Deng, Tianshu Liu, et al.
International Journal of Clinical and Experimental Pathology|June 6, 2015
Activation of FOXO3a suggests good prognosis of patients with radically resected gastric cancerShan Yu, Yiyi Yu, Yihong Sun, et al.
European Journal of Cancer (Oxford, England : 1990)|August 31, 2021
Treatment strategy for myocarditis in patients using immune checkpoint inhibitors or combined anti-vascular endothelial growth factor therapy by clinical severityQing Liu, Yiyi Yu, Jinyi Lin, et al.
BMC Cancer|April 4, 2023
Does resection after neoadjuvant chemotherapy of docetaxel, oxaliplatin, and S-1 (DOS regimen) benefit for gastric cancer patients with single non-curable factor? a multicenter, prospective cohort study (Neo-REGATTA)Yuehong Cui, Yiyi Yu, Song Zheng, et al.
Journal of Translational Medicine|August 29, 2024
Tofacitinib for the treatment of immune-related adverse events in cancer immunotherapy: a multi-center observational studyQing Liu, Mengling Liu, Zhiguo Zou, et al.
Pageof 30